12 Best Multibagger Stocks to Buy Right Now

7) ADMA Biologics, Inc. (NASDAQ:ADMA)

Number of Hedge Fund Holders: 25

One-year Return: ~284%

Average Upside Potential: ~42%

Market Cap as of 30^th December: $4.13 billion

ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company, that is engaged in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.

Industry experts believe that a strong sales outlook for Asceniv should drive growth for ADMA Biologics, Inc. (NASDAQ:ADMA) in the near to medium term. Asceniv is a proprietary, FDA-approved immune globulin intravenous (IGIV) therapy. It mainly treats patients with primary humoral immunodeficiency (PI), a group of disorders characterized by impaired antibody production.

Analysts believe that the ongoing post-marketing study for Asceniv is expected to provide a label expansion opportunity and include pediatric-aged PI patients. Notably, the potential label expansion of Asceniv is expected to boost revenue growth. ADMA Biologics, Inc. (NASDAQ:ADMA) remains focused on increasing Asceniv’s supply. If successful, Asceniv will be responsible for advancing its margin expansion and earnings growth. Asceniv complements Bivigam®, ADMA Biologics, Inc. (NASDAQ:ADMA)’s other IGIV product, allowing ADMA Biologics, Inc. (NASDAQ:ADMA) to serve a broader spectrum of patients having varying immune needs.

Asceniv is enriched with targeted antibodies, primarily against respiratory syncytial virus (RSV), placing it apart from standard IGIV therapies. Because of its specialized manufacturing process and targeted antibody profile, Asceniv commands a higher price point in comparison to traditional IGIV therapies, fueling per-unit revenue.